Categories | Inventors

ARAC-8C cell line

 

OHSU # 1626-A

Summary:

Technology Overview:

Two nucleoside transport-deficient cell lines were developed through isolation from a hypoxanthine-guanine phosphoribosyltransferase-deficient derivative of wild type CEM cells (a human T lymphoblast cell line originally derived from a patient with acute lymphocytic leukemia).  The Ara-C/8C and TUB-4D clones were isolated by virtue of their resistance to 8 µM arabinosylcytosine and 4µM tubercidin, respectively.  One cell line completely deficient in deoxycytidine kinase activity, the Ara-C/8D clone, is a clonal derivative of an hypoxanthine-guanine phosphoribosyltransferase-deficient parent CEM cell line originally isolated in semi-solid agarose containing 8µM arabinosylcytosine.  The Ara-C/8C and TUB-4D cell lines are cross-resistant to a spectrum of cytotoxic nucleosides to which parental and Ara-C/8D cell are sensitive. 

Cytarabine (Ara-C), a pyrimidine analog, is a conventional anti-cancer chemotherapeutic commonly used for the treatment of acute myeloid leukemia.  Although Ara-C treatment often induces partial or complete remission of cancerous tissue, many patients eventually develop resistance.  Ara-C/8C cells demonstrate cross-resistance to gemcitabine and 2’, 3’-dideoxycytidine.  Therefore, this cell line may be useful for research into nucleoside transport deficiencies as well as anti-cancer chemotherapeutic analysis.

Links/Publications:  Ulllman et al., J Biol Chem. 1988 Sep 5;263(25):12391-6. 

Licensing Opportunity:  The cell lines are available for non-exclusive licensing.

 

Inventors:

Related Technologies:

  • OHSU # 1626 — CEM cell lines genetically deficient in either nucleoside transport or deoxycytidine kinase activity
  • OHSU # 1626-B — TUB-4D cell line
  • OHSU # 1626-C — ARAC-8D cell line

Categories:

For more information, contact:

Trina Voss
Technology Development Manager
503-494-9839

OptionPrice
(terms)  $1000.00